Post-earnings recap
Reported
Thu, Aug 5, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
ResMed's earnings report shows a solid EPS beat, indicating better-than-expected profitability. However, the stock fell by 2.13%, likely due to the lack of revenue details and guidance. Investors may be cautious given the ongoing supply chain challenges mentioned by management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.35 | N/A | +8.17% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a positive outlook on product demand despite supply chain issues. They emphasized their commitment to innovation.
Management highlighted ongoing demand for respiratory products.
They noted challenges in supply chain but remain focused on innovation.